Comparative Pharmacology
Head-to-head clinical analysis: EVALOSE versus HYDROXYZINE PAMOATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVALOSE versus HYDROXYZINE PAMOATE.
EVALOSE vs HYDROXYZINE PAMOATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EVALOSE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity by blocking the reuptake of serotonin at the presynaptic neuron, thereby increasing serotonin levels in the synaptic cleft.
Hydroxyzine pamoate is a piperazine derivative with antihistamine (H1 receptor antagonist) and anticholinergic properties. It also has sedative, anxiolytic, and antiemetic effects, likely mediated through suppression of subcortical regions of the central nervous system.
Adults: 1-2 tablets (5-10 mg) orally once daily, adjusted to maximum 20 mg/day.
Oral: 50-100 mg every 6 hours as needed for pruritus or anxiety; maximum 600 mg/day. IM: 25-100 mg every 4-6 hours as needed.
None Documented
None Documented
Terminal elimination half-life is 12 hours (range 10-14 h); clinically significant for once-daily dosing in most patients with normal renal function; extend dosing interval in renal impairment
Terminal elimination half-life is approximately 20 hours (range 14-25 hours) in adults; may be prolonged in elderly or hepatic impairment.
Renal: 70% unchanged; Biliary/Fecal: 20% as metabolites; 10% other
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal elimination accounts for approximately 50% of metabolites.
Category C
Category A/B
Antihistamine
Antihistamine